Among other executive moves are two Roche departures, to Oak Hill Bio and Pharmanovia, and three Moderna departures, to ...
Menarini CEO Elcin Barker Ergun kept Stemline intact, licensed an obesity drug and, with NewAmsterdam, secured the first ...
Today marks the start of Global Biosimilars Week 2026, the latest instalment of the annual campaign from the IGBA that this ...
The FDA approved the anti-IL6R drug for thyroid eye disease, but drugs targeting IGF-1R are still regarded as the gold ...
NervGen's RESTORE trial, which dosed its first patient Oct. 12, is a rare pivotal spinal cord injury study built on the ...
Industry groups largely support the FDA’s proposal to let distributed manufacturing networks register as one establishment, ...
The Expert Panel for Cosmetic Ingredient Safety accepted the recommendations for prostaglandin analogues from the Read-Across ...
Fresenius Kabi has announced a leadership change that will see Marc-Alexander Mahl take over responsibility of the business ...
Bipartisan House legislation would exempt ostomy and urological supplies from Medicare competitive bidding for five years, as ...
A rundown of the ten biggest mid-cap risers and decliners of the year to date, with catalysts which could shape big pharma’s ...
The European Medicines Agency’s human medicines committee has endorsed Eli Lilly’s once-daily pill for obesity and type 2 ...
A new approach intended to speed up the evaluation of drug marketing applications in the EU has passed its first test, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results